RU2723486C2 - Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения диабета - Google Patents

Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения диабета Download PDF

Info

Publication number
RU2723486C2
RU2723486C2 RU2017116106A RU2017116106A RU2723486C2 RU 2723486 C2 RU2723486 C2 RU 2723486C2 RU 2017116106 A RU2017116106 A RU 2017116106A RU 2017116106 A RU2017116106 A RU 2017116106A RU 2723486 C2 RU2723486 C2 RU 2723486C2
Authority
RU
Russia
Prior art keywords
compound
alkyl
diabetes
insulin
formula
Prior art date
Application number
RU2017116106A
Other languages
English (en)
Russian (ru)
Other versions
RU2017116106A3 (enExample
RU2017116106A (ru
Inventor
Лин Ганьон
Брижит Груа
Original Assignee
Прометик Фарма Смт Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прометик Фарма Смт Лимитед filed Critical Прометик Фарма Смт Лимитед
Publication of RU2017116106A publication Critical patent/RU2017116106A/ru
Publication of RU2017116106A3 publication Critical patent/RU2017116106A3/ru
Application granted granted Critical
Publication of RU2723486C2 publication Critical patent/RU2723486C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2017116106A 2014-10-10 2015-10-08 Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения диабета RU2723486C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062526P 2014-10-10 2014-10-10
US62/062,526 2014-10-10
PCT/CA2015/000531 WO2016054726A1 (en) 2014-10-10 2015-10-08 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

Publications (3)

Publication Number Publication Date
RU2017116106A RU2017116106A (ru) 2018-11-12
RU2017116106A3 RU2017116106A3 (enExample) 2019-02-13
RU2723486C2 true RU2723486C2 (ru) 2020-06-11

Family

ID=55652427

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017116106A RU2723486C2 (ru) 2014-10-10 2015-10-08 Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения диабета

Country Status (21)

Country Link
US (1) US10105331B2 (enExample)
EP (1) EP3203998B1 (enExample)
JP (1) JP6676629B2 (enExample)
KR (1) KR20170066614A (enExample)
CN (1) CN106999458B (enExample)
AR (1) AR102248A1 (enExample)
AU (1) AU2015330643B2 (enExample)
BR (1) BR112017007420A2 (enExample)
CA (1) CA2963276A1 (enExample)
DK (1) DK3203998T3 (enExample)
ES (1) ES2875336T3 (enExample)
IL (1) IL251392B (enExample)
MX (1) MX376872B (enExample)
PH (1) PH12017500662B1 (enExample)
PL (1) PL3203998T3 (enExample)
PT (1) PT3203998T (enExample)
RU (1) RU2723486C2 (enExample)
SG (1) SG11201702812PA (enExample)
TW (1) TWI699201B (enExample)
UY (1) UY36354A (enExample)
WO (1) WO2016054726A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201702812PA (en) * 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
US10391073B2 (en) * 2014-11-12 2019-08-27 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
CA3112073A1 (en) 2018-10-11 2020-04-16 Basf As Aromatic compounds and pharmaceutical uses thereof
US20240043372A1 (en) * 2020-10-06 2024-02-08 Pharmaceutique Ingenew Inc. Substituted aromatic compounds and pharmaceutical compositions thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710178A (en) * 1991-10-21 1998-01-20 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS, and anemia
WO2006031931A2 (en) * 2004-09-15 2006-03-23 The President And Fellows Of Harvard College Reducing er stress in the treatment of obesity and diabetes
WO2012097428A1 (en) * 2010-10-27 2012-07-26 Prometic Biosciences Inc. Compounds and pharmaceutical compositions for uses in diabetes
RU2521284C2 (ru) * 2003-02-13 2014-06-27 Веллстат Терапьютикс Корпорейшн Соединение для лечения метаболических расстройств
WO2014138906A1 (en) * 2013-03-15 2014-09-18 Prometic Biosciences Inc. Substituted aromatic compounds and related method for the treatment of fibrosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT509045B1 (de) * 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale
JP2012072136A (ja) * 2010-09-03 2012-04-12 Erina Co Inc 細胞内代謝促進用組成物、その組成物を含有する糖代謝又は脂質代謝疾患の予防及び／又は治療用医薬製剤、機能性食品及び健康食品
SG11201702812PA (en) * 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710178A (en) * 1991-10-21 1998-01-20 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS, and anemia
RU2521284C2 (ru) * 2003-02-13 2014-06-27 Веллстат Терапьютикс Корпорейшн Соединение для лечения метаболических расстройств
WO2006031931A2 (en) * 2004-09-15 2006-03-23 The President And Fellows Of Harvard College Reducing er stress in the treatment of obesity and diabetes
WO2012097428A1 (en) * 2010-10-27 2012-07-26 Prometic Biosciences Inc. Compounds and pharmaceutical compositions for uses in diabetes
WO2014138906A1 (en) * 2013-03-15 2014-09-18 Prometic Biosciences Inc. Substituted aromatic compounds and related method for the treatment of fibrosis

Also Published As

Publication number Publication date
RU2017116106A3 (enExample) 2019-02-13
WO2016054726A1 (en) 2016-04-14
EP3203998A4 (en) 2018-06-20
CN106999458B (zh) 2021-04-13
EP3203998B1 (en) 2021-03-10
SG11201702812PA (en) 2017-05-30
ES2875336T3 (es) 2021-11-10
KR20170066614A (ko) 2017-06-14
US10105331B2 (en) 2018-10-23
IL251392A0 (en) 2017-05-29
AR102248A1 (es) 2017-02-15
EP3203998A1 (en) 2017-08-16
MX376872B (es) 2025-03-07
RU2017116106A (ru) 2018-11-12
TW201618763A (zh) 2016-06-01
PL3203998T3 (pl) 2021-09-27
MX2017004738A (es) 2017-08-10
AU2015330643A1 (en) 2017-05-04
UY36354A (es) 2016-06-01
PT3203998T (pt) 2021-06-07
PH12017500662B1 (en) 2022-08-19
IL251392B (en) 2020-11-30
CN106999458A (zh) 2017-08-01
JP6676629B2 (ja) 2020-04-08
PH12017500662A1 (en) 2017-10-02
AU2015330643B2 (en) 2020-05-14
TWI699201B (zh) 2020-07-21
US20170209399A1 (en) 2017-07-27
JP2017530182A (ja) 2017-10-12
BR112017007420A2 (pt) 2018-01-16
DK3203998T3 (da) 2021-05-31
CA2963276A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
AU2011356584B2 (en) Compounds and pharmaceutical compositions for uses in diabetes
EP4125896B1 (en) Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
RU2723486C2 (ru) Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения диабета
US20080262088A1 (en) Methods, compounds, and compositions for treating metabolic disorders and diabetes
KR20050097537A (ko) 당뇨병 치료제
CN101668530A (zh) 激活irs-1和akt的方法
Zhu et al. GPR119 agonists: a novel strategy for type 2 diabetes treatment
WO2005097103A2 (en) Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors
JP5252585B2 (ja) 代謝障害の治療のための化合物
JP2009506043A (ja) Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤
CA2598491A1 (en) Diastereoisomers of 4-hydroxyisoleucine and uses thereof
HK1236421B (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
WO2011002011A1 (ja) Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬
US20240366625A1 (en) Compositions containing and therapies using bempedoic acid and tolvaptan
CN105232544A (zh) 一种抗糖尿病的口服药物组合物

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner